Xbrane strengthens the organization with the appointment of Erik Domines as General Counsel

Corporate Information

English

News

Staff change

Xbrane Biopharma AB (publ) (“Xbrane or “the Company”) announces the appointment of Erik Domines as General Counsel. Erik brings significant experience from the Life Science sector.

Erik brings significant experience from various Senior roles, most recently from Business development in Legal Operations and was In-house lawyer 2009-2014 and General Counsel between 2014-2018 at Recipharm AB (publ) in the life science sector.

His education includes a bachelor’s degree in law from Stockholm University & General Counsel mini-MBA. Erik is also a certified Board member and certified Secretary of the Board.

Erik Domines will report to the CEO, join the management team as he starts his work effective today March 15th.

I welcome Erik to Xbrane and am convinced his expertise will make a significant contribution to Xbranes development as we prepare for the next phase of Xbranes growth”, Martin Åmark, CEO announces.

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.